Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria

balköse, gülçin; Adaleti, Rıza; toptan, hande; DOGAN, OZLEM; aksaray, sebahat

doi:10.14744/hnhj.2019.55706

Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria

Hande TOPTAN, (Sakarya Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Sakarya, Türkiye)

Gülçin BALKÖSE, (Muğla Sıtkı Koçman Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji Kliniği, Muğla, Türkiye)

Özlem DOĞAN, (Koç Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, İstanbul, Türkiye)

Rıza ADALETİ, (Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji Kliniği, İstanbul, Türkiye)

Sebahat AKSARAY (Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji Kliniği, İstanbul, Türkiye)

Haydarpaşa Numune Medical Journal

5 1

Yıl: 2020 Cilt: 60 Sayı: 4 Sayfa Aralığı: 352 - 356 Metin Dili: İngilizce DOI: 10.14744/hnhj.2019.55706 İndeks Tarihi: 11-05-2021

Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria

Öz:

Introduction: Expanded spectrum beta-lactamase is a critical source that is limiting the using areas of beta-lactam antibi-otics by hydrolysing them. The method to be used for accurate detection of ESBL production is significant. CLSI and EUCAST are the two most commonly used standards for the determination of antibiotic susceptibility. This study aimed to investigate the sensitivity and specificity of these standards for ESBL detection.Methods: This study includes 76 ESBL producers and 74 ESBL negative strains, which were isolated from urine specimens that sent to the Medical Microbiology Laboratory of Haydarpasa Numune Training and Research Hospital from April to July 2014. For screening tests, ceftazidime (10μg and 30μg), cefotaxime (5μg and 30μg), ceftriaxone (30μg), cefpodoxime (10μg), cefepime (30μg) ve aztreonam (30μg) disks; for confirmation tests double-disk synergy and combination disk method were used. For molecular confirmation tests, CTX-M, TEM and SHV resistance genes were investigated by polymerase chain reaction.Results: ESBL producing isolates were found at 86.8% as CTX-M, 47.4% as TEM and 9.2% as SHV. More than one resistance gene was detected in some isolates. Beta-lactam susceptibilities of ESBL producers with CLSI and EUCAST breakpoints were 29.2% and 19.7% for ceftazidime, 14.5% and 15.8% for cefepime, 2.6% and 13.2% for aztreonam, respectively. Among thescreening disks, cefpodoxime (interpreted by EUCAST criteria), showed the highest sensitivity and specificity. This was followed by cefpodoxime (CLSI), cefotaxime and ceftriaxone with similar sensitivity and specificity for both standards.Discussion and Conclusion: There was no significant difference between CLSI and EUCAST in determining ESBL production. The suggestion of EUCAST that using different disks for screening and confirmation tests increases the sensitivity of detecting ESBL, especially in ceftazidime; however, it may cause practical difficulties. For both standards, the use of cefpodoxime,cefotaxime or ceftriaxone disks in screening and; cefotaxime and cefotaxime- clavulanate disks in confirmation tests will provide more accurate results.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rawat D, Nair D. Extended-spectrum β-lactamases in Gram Negative Bacteria. J Glob Infect Dis 2010;2:263–74.
2. Dhillon RH, Clark J. ESBLs: A Clear and Present Danger? Crit Care Res Pract 2012;2012:625170.
3. Taşova Y. Gram negatif enterik bakteri enfeksiyonlarının yöne- timi, ANKEM Derg 2011;25:34–44.
4. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Na- gler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66:398–407.
5. CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
6. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 7.1, 2017. Available at: http://www.eucast.org/ast_of_bacteria/previous_versions_of_docu- ments/. Accessed 20 Nov, 2018.
7. Blandino G, Mastrojeni S, Inturri R, Sciacca A, Nicoletti G. An- timicrobial susceptibility of strains of Enterobactericeae iso- lated from bloodstream infections using current CLSI and EUCAST breakpoints. Health 2014;6:153–7.
8. Rodríguez-Baño J, Picón E, Navarro MD, López-Cerero L, Pascual A; ESBL-REIPI Group. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect 2012;18:894–900.
9. Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2013;68:2092–8.
10. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M. Com- parison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2012;67:159–66.
11. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008;13:19044.
12. Görgeç S, Kuzucu Ç, Otlu B, Yetkin F, Ersoy Y. Genişlemiş spek- trumlu beta-laktamaz üreten nozokomiyal Escherichia coli izolatlarında beta-laktamaz gen oranları ve klonal ilişkinin araştırılması [Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta- lactamase producing nosocomial Escherichia coli isolates].Mikrobiyol Bul 2015;49:15–25.
13. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002;46:1–11.

APA	toptan h, balköse g, DOGAN O, Adaleti R, aksaray s (2020). Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. , 352 - 356. 10.14744/hnhj.2019.55706
Chicago	toptan hande,balköse gülçin,DOGAN OZLEM,Adaleti Rıza,aksaray sebahat Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. (2020): 352 - 356. 10.14744/hnhj.2019.55706
MLA	toptan hande,balköse gülçin,DOGAN OZLEM,Adaleti Rıza,aksaray sebahat Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. , 2020, ss.352 - 356. 10.14744/hnhj.2019.55706
AMA	toptan h,balköse g,DOGAN O,Adaleti R,aksaray s Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. . 2020; 352 - 356. 10.14744/hnhj.2019.55706
Vancouver	toptan h,balköse g,DOGAN O,Adaleti R,aksaray s Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. . 2020; 352 - 356. 10.14744/hnhj.2019.55706
IEEE	toptan h,balköse g,DOGAN O,Adaleti R,aksaray s "Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria." , ss.352 - 356, 2020. 10.14744/hnhj.2019.55706
ISNAD	toptan, hande vd. "Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria". (2020), 352-356. https://doi.org/10.14744/hnhj.2019.55706

APA	toptan h, balköse g, DOGAN O, Adaleti R, aksaray s (2020). Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. Haydarpaşa Numune Medical Journal, 60(4), 352 - 356. 10.14744/hnhj.2019.55706
Chicago	toptan hande,balköse gülçin,DOGAN OZLEM,Adaleti Rıza,aksaray sebahat Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. Haydarpaşa Numune Medical Journal 60, no.4 (2020): 352 - 356. 10.14744/hnhj.2019.55706
MLA	toptan hande,balköse gülçin,DOGAN OZLEM,Adaleti Rıza,aksaray sebahat Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. Haydarpaşa Numune Medical Journal, vol.60, no.4, 2020, ss.352 - 356. 10.14744/hnhj.2019.55706
AMA	toptan h,balköse g,DOGAN O,Adaleti R,aksaray s Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. Haydarpaşa Numune Medical Journal. 2020; 60(4): 352 - 356. 10.14744/hnhj.2019.55706
Vancouver	toptan h,balköse g,DOGAN O,Adaleti R,aksaray s Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria. Haydarpaşa Numune Medical Journal. 2020; 60(4): 352 - 356. 10.14744/hnhj.2019.55706
IEEE	toptan h,balköse g,DOGAN O,Adaleti R,aksaray s "Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria." Haydarpaşa Numune Medical Journal, 60, ss.352 - 356, 2020. 10.14744/hnhj.2019.55706
ISNAD	toptan, hande vd. "Detection of the Presence of Extended-Spectrum Beta-Lactamase Enzyme in Gram-negative Bacteria According to CLSI and EUCAST Criteria". Haydarpaşa Numune Medical Journal 60/4 (2020), 352-356. https://doi.org/10.14744/hnhj.2019.55706